Defining the critical hurdles in cancer immunotherapy

Journal of Translational Medicine

Commentary

Lindy G Durrant¹  Jared A Gollob²  Michael B Atkins³  Axel Hoos⁴  Michael Papamichail⁵  Jill O'Donnell-Tormey⁶  Samir N Khleif⁷  Per Thor Straten⁸  Graham Pawelec⁹  Xuetao Cao^1,10  Shukui Qin^1,11  Brad Nelson^1,12  Heinz Zwierzina^1,13  Hiroshi Shiku^1,14  Steinar Aamdal^1,15  Kunle Odunsi^1,16  Ignacio Melero^1,17  James H Finke^1,18  Andrea Nicolini^1,19  Harry Dolstra^2,20  Glenn Dranoff^2,21  Michael J Mastrangelo^2,22  Tanja de Gruijl^2,23  F Stephen Hodi^2,24  Antoni Ribas^2,25  Patrick Hwu^2,26  Beatrix Kotlan^2,27  Cristina Maccalli^2,28  Rolf Kiessling^2,29  Elizabeth M Jaffee^3,30  Giuseppe Masucci^3,31  Jonathan L Bramson^3,32  Pawel Kalinski^3,33  Hideaki Tahara^3,34  Hauke Winter^3,35  William E Carson^3,36  Alfred E Chang^3,37  Ernest Borden^3,38  Michael T Lotze^3,39  Lisa H Butterfield^3,39  Ulrich Keilholtz^4,40  Rik J Scheper^4,41  Cornelius Melief^4,42  Jon M Wigginton^4,43  Yutaka Kawakami^4,44  Pedro J Romero^4,45  Bernard A Fox^4,46  Paul von Hoegen^4,47  Marij JP Welters^4,48  Sjoerd H van Der Burg^4,49  Christian Ottensmeier^5,50  Dainius Characiejus^5,51  Lothar Bergmann^5,52  Robert O Dillman^5,53  Jerome Galon^5,54  Guido Kroemer^5,55  Neil Berinstein^5,56  Harpreet Singh-Jasuja^5,57  Mohamed L Salem^5,58  Ruggero Ridolfi^5,59  Ena Wang^6,60  Francesco M Marincola^6,60  Laurence Zitvogel^6,61  Cécile Gouttefangeas^6,62  Jirina Bartunkova^6,63  Weihua Xiao^6,64  Zhigang Tian^6,65  Barbara Seliger^6,66  Dolores J Schendel^6,67  Cristina C Bonorino^6,68  Ronald B Herberman^6,69  Fabio Grizzi^7,70  Enrico Proietti^7,71  Lloyd J Old^7,72  Padmanee Sharma^7,73  Michele Maio^7,74  Paolo Antonio Ascierto^7,75  Jedd D Wolchok^7,76  James P Allison^7,77  Gerd Ritter^7,78  Jens-Peter Marschner^7,79  Wenru Song^8,80  Michele Guida^8,81  Michael I Nishimura^8,82  Pamela S Ohashi^8,83  George Coukos^8,84  Carl H June^8,85  Rejean Lapointe^8,86  Howard L Kaufman^8,87  Koji Kawakami^8,88  Hyam I Levitsky^8,89  Tara Withington^9,90  Kohzoh Imai^9,91  Robert Rees^9,92  Christoph Huber^9,93  Mary L Disis^9,94  Giorgio Parmiani^9,95  Licia Rivoltini^9,96  Cedrik M Britten^9,97  Kristen Hege^9,98  William J Murphy^9,99  Thomas F Gajewski^1,10,100  Leif Håkansson^1,10,101  A Raja Choudhury^1,10,102  Sylvia Janetzki^1,10,103 

[1] Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK;Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA;Beth Israel Deaconess Medical Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USA;Bristol-Myers Squibb Company, Wallingford, Connecticut, USA;Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece;Cancer Research Institute, New York, NY, USA;Cancer Vaccine Section, NCI, NIH, Bethesda, MD, USA;Center for Cancer Immune Therapy (CCIT), Department of Hematology, Herlev Hospital, Herlev, Denmark;Center for Medical Research, University of Tuebingen, Tuebingen, Germany;Chinese Academy of Medical Sciences, Beijing, China;Institute of Immunology, National Key Laboratory of Medical Immunology, Second Military Medical University, Shanghai, China;Chinese PLA Cancer Center, Nanjing, China;Deeley Research Centre, BC Cancer Agency, Victoria, BC, Canada;Department Haematology and Oncology Innsbruck Medical University, Innsbruck, Austria;Department of Cancer Vaccine, Mie University Graduate School of Medicine, Mie, Japan;Department of Immuno-gene Therapy, Mie University Graduate School of Medicine, Mie, Japan;Department of Clinical Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway;Department of Gynecologic Oncology, Tumor Immunology and Immunotherapy Program, Roswell Park Cancer Institute, Buffalo, NY, USA;Department of Immunology, CIMA, CUN and Medical School University of Navarra, Pamplona, Spain;Department of Immunology, Cleveland Clinic Foundation, Cleveland, OH, USA;Department of Internal Medicine, University of Pisa, Santa Chiara Hospital, Pisa, Italy;Department of Laboratory Medicine, Nijmegen Centre for Molecular Life Sciences, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands;Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA;Harvard Medical School, Boston, MA, USA;Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA;Department of Medical Oncology, VU Medical Center, Cancer Center Amsterdam Amsterdam, The Netherlands;Department of Medicine, Harvard Medical School, Boston, MA, USA;Dana-Farber Cancer Institute, Boston, MA, USA;Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA;Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA;Department of Molecular Immunology and Toxicology, Center of Surgical and Molecular Tumor pathology, National Institute of Oncology, Budapest, Hungary;Department of Molecular Oncology, Foundation San Raffaele Scientific Institute, Milan, Italy;Department of Oncology - Pathology, Cancer Center Karolinska, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden;Department of Oncology, the Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA;Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden;Department of Pathology, McMaster University, Hamilton, ON, Canada;Department of Surgery University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA;Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan;Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany;Department of Surgery, Ohio State University, Columbus, OH, USA;Department of Surgery, University of Michigan Medical Center, Ann Arbor, MI, USA;Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA;Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH, USA;Departments of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA;Department of Surgery University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA;Department of Immunology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA;Dept. of Hematology and Medical Oncology, Charité Comprehensive Cancer Center, Berlin, Germany;Dept. of Pathology, VU University Medical Center, Amsterdam, The Netherlands;Deptartment of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, the Netherlands;Discovery Medicine-Oncology, Bristol-Myers Squibb Company, Princeton, New Jersey, USA;Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan;Division of Clinical Onco-Immunology, Ludwig Center for Cancer Research of the University of Lausanne, Epalinges, Switzerland;Earle A. Chiles Research Institute, Robert W. Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA;Department of Molecular Microbiology and Immunology and Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA;Euraccine Consulting Group, Brussels, Belgium;Experimental Cancer Immunology and Therapy, Department of Clinical Oncology (K1-P), Leiden University Medical Center, Leiden, The Netherlands;Experimental Cancer Immunology and Therapy, Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands;Experimental Cancer Medicine Centre, University of Southampton Faculty of Medicine, Southampton, UK;Faculty of Medicine, Vilnius University, Vilnius, Lithuania;Goethe Universität Frankfurt Am Main,Medizinische Klinik II, Frankfurt Am Main, Germany;Hoag Institute for Research and Education, Hoag Cancer Institute, Newport Beach, CA, USA;INSERM U872, Cordeliers Research Center, Paris, France;INSERM, U848, Institut Gustave Roussy, Villejuif, France;IRX Therapeutics, New York, NY, USA;Immatics Biotechnologies GmbH, Tübingen, Germany;Immunology and Biotechnology Unit, Department of Zoology, Faculty of Science, Tanta University, Egypt;Immunoterapia e Terapia Cellulare Somatica, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola (FC), Italy;Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, MD, USA;Center for Human Immunology (CHI), NIH, Bethesda, MD, USA;Institut Gustave Roussy, Center of Clinical Investigations CICBT507, Villejuif, France;Institute for Cell Biology, Department of Immunology, University of Tuebingen, Tuebingen, Germany;Institute of Immunology, FOCIS Center of Excellence, 2nd Medical School, Charles University, Prague, Czech Republic;Institute of Immunology, School of Life Science, University of Science and Technology of China, Hefei, China;Institute of Immunology, School of Life Sciences, University of Science & Technology of China, Hefei, China;Institute of Immunopharmacology & Immunotherapy, School of Pharmaceutical Sciences, Shandong University, Jinan, China;Institute of Medical Immunology, Halle, Germany;Institute of Molecular Immunology and Clinical Cooperation Group "Immune Monitoring", Helmholtz Centre Munich, German Research Center for Environmental Health, Munich, Germany;Instituto Nacional para o Controle do Câncer, Instituto de Pesquisas Biomédicas, PUCRS Faculdade de Biociências, PUCRS, Porto Alegre RS, Brazil;Intrexon Corporation, Germantown, MD, USA;Istituto Clinico Humanitas, IRCCS, Milan, Italy;Istituto Superiore di Sanita', Rome, Italy;Ludwig Institute for Cancer Research, New York, NY, USA;MD Anderson Cancer Center, Houston, TX, USA;Medical Oncology and Immunotherapy, Department of Oncology, University, Hospital of Siena, Istituto Toscano Tumori, Siena, Italy;Medical Oncology and Innovative Therapy, Instituto Nazionale Tumori-Fondazione 'G. Pascale', Naples, Italy;Memorial Sloan-Kettering Cancer Center, New York, NY, USA;Memorial Sloan-Kettering Cancer Center, New York, NY, USA;Howard Hughes Medical Institute, New York, NY, USA;Memorial Sloan-Kettering Cancer Center, New York, NY, USA;Ludwig Institute for Cancer Research, New York, NY, USA;Merck KGaA, Darmstadt, Germany;Millennium: The Takeda Oncology Company, Cambridge, MA, USA;Oncology Department, Oncology Institute Bari, Italy;Oncology Institute, Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL, USA;Ontario Cancer Institute/University Health Network, Toronto, ON, Canada;Ovarian Cancer Research Center, University of Pennsylvania Medical Center, Philadelphia, A, USA;Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA;Research Center, University Hospital, Université de Montréal (CRCHUM), Montréal, Québec, Canada;Institut du Cancer de, Montréal, Montréal, Québec, Canada;Rush University Cancer Center, Rush University Medical Center, Chicago, IL, USA;School of Medicine and Public Health, Kyoto University, Kyoto, Japan;School of Medicine, Oncology Center, Johns Hopkins University, Baltimore, MD, USA;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK;Translational Oncology & Immunology Centre TRON at the Mainz University Medical Center, Mainz, Germany;Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, WA, USA;Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, San Raffaele Scientific Institute, Milan, Italy;Unit of Immunotherapy of Human Tumors, IRCCS Foundation, Istituto Nazionale Tumori, Milan, Italy;University Medical Center Mainz, III. Medical Department, Mainz, Germany;Ribological GmbH, Mainz, Germany;University of California, San Francisco, CA and Celgene Corporation, San Francisco, CA, USA;University of California-Davis Medical Center, Sacramento, CA, USA;University of Chicago Medical Center, Chicago, IL, USA;University of Lund, Lund, Sweden;CanImGuide Therapeutics AB, Hoellviken, Sweden;University of Queensland, Brisbane, Australia;ZellNet Consulting, Inc., Fort Lee, NJ, USA;

关键词: Cancer Immunotherapy;    Chimeric Antigen Receptor;    Small Business Innovation Research;    Immunotherapeutic Agent;    Combination Immunotherapy;   

DOI  :  10.1186/1479-5876-9-214

 received in 2011-05-02, accepted in 2011-12-14,  发布年份 2011

来源: Springer

【 摘 要 】

Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.

【 授权许可】

CC BY   
© Fox et al; licensee BioMed Central Ltd. 2011